Cadila gets EIR from USFDA for Ahmedabad biologics unit
NO OBSERVATION
New Delhi: Drug firm Cadila Healthcare has recently announced that its biologics manufacturing facility at Ahmedabad has received Establishment Inspection Report(EIR) from the US health regulator with zero observations.
"The company's biologics manufacturing facility located at the Zydus Biotech Park in Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying the successful closure of the audit," Cadila Healthcare said in a filing to BSE.
The plant completed the USFDA audit from August 14-24 2018 with zero 483 observations, it added.
Read Also: Zydus Cadila gets USFDA nod for Desoximetasone cream
New Delhi: Drug firm Cadila Healthcare has recently announced that its biologics manufacturing facility at Ahmedabad has received Establishment Inspection Report(EIR) from the US health regulator with zero observations.
"The company's biologics manufacturing facility located at the Zydus Biotech Park in Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying the successful closure of the audit," Cadila Healthcare said in a filing to BSE.
The plant completed the USFDA audit from August 14-24 2018 with zero 483 observations, it added.
Read Also: Zydus Cadila gets USFDA nod for Desoximetasone cream
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd